ClinicalTrials.Veeva

Menu

A Study Comparing Viscosupplementation and Corticosteroid Injections for Knee Osteoarthritis

L

LifeMark Health

Status

Unknown

Conditions

Osteoarthritis, Knee

Treatments

Device: Hylan G-F 20 (Synvisc One)
Drug: Methylprednisolone (Corticosteroid)

Study type

Interventional

Funder types

Other

Identifiers

NCT01132677
HA-CS-OA1

Details and patient eligibility

About

Do differences exist between patients who receive a single intra-articular injection of corticosteroid versus patients who receive a single intra-articular injection of hyaluronic acid for the treatment of knee osteoarthritis at 1, 3 and 6 weeks, and 3 and 6 months post injection?

Full description

OBJECTIVES

Primary i. To determine if patients' VAS "pain while walking" is different at 6 weeks post-injection in patients who receive a single injection of methylprednisolone acetate (MPA) versus patients who receive a single injection of Hylan G-F 20 (Synvisc One™) for treatment of knee OA.

Secondary i. To determine if differences in VAS "pain while walking" scores exist at 1 and 3 weeks, and 3 and 6 months post injection between MPA and HA patients.

ii. To determine if differences in VAS "pain at rest" scores exist at 1, 3 and 6 weeks and 3 and 6 months post injection between MPA and HA patients.

iii. To determine if differences in VAS "pain with stairs" scores exist at 1, 3 and 6 weeks and 3 and 6 months post injection between MPA and HA patients.

iii. To determine if differences in KOOS questionnaire scores exist at 6 weeks, 3 months and 6 months post injection between MPA and HA patients.

iv. To determine if differences in WOMAC questionnaire scores exist at 6 weeks, 3 months, and 6 months post injection between MPA and HA patients.

v. To determine if differences in adverse events exist at 1, 3 and 6 weeks, and 3, and 6 months post injection between MPA and HA patients.

vi. To track the number of patients who receive additional injections after 3 months following their index injection.

Enrollment

78 estimated patients

Sex

All

Ages

19 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Clinical

    • 19-75 years of age (inclusive)
    • Symptomatic OA (1 of the following: pain, stiffness, or swelling)
    • Evidence of grade I, II or III OA on radiographic images according to Kellgren-Lawrence grading scale.

Exclusion criteria

  • Clinical

    • Previous surgery on either knee (not including a diagnostic arthroscopy arthroscopy or simple partial meniscectomy)
    • Intra-articular treatment within the last 3 months
    • Ipsilateral cruciate or collateral ligament injury within past 3 months, or evidence of ligament laxity
    • Inflamed knee or pronounced effusion
    • Allergy to birds, eggs, avian proteins or known HA or corticosteroid
    • Venous or lymphatic stasis
    • Skin condition in the injection area
    • Evidence of infection in the affected joint
    • History of crystalline arthropathy or inflammatory arthritis
    • Pregnant or nursing
    • Third Party, Medical Legal or Workers' Compensation Board
    • Patient unable to understand English or unable to providing informed consent

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

78 participants in 2 patient groups

Hyaluronic Acid (HA) Injection
Active Comparator group
Description:
Patients allocated to the HA group will receive a single IA injection Hylan G-F 20 Synvisc One™ (1 injection of 6cc's). All injections will be administered as outlined on the company label. Aspiration of the knee will not be performed.
Treatment:
Device: Hylan G-F 20 (Synvisc One)
Corticosteroid Injection
Active Comparator group
Description:
Patients allocated to the corticosteroid injection will receive a single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label. Aspiration of the knee will not be performed.
Treatment:
Drug: Methylprednisolone (Corticosteroid)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems